ribociclib plus endocrine therapy boosts survival of hr /her2- breast cancer
Published 5 years ago • 3.6K plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
2:00
ribociclib in early breast cancer | nejm
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
4:10
what’s new with her2-neu inhibition
-
4:12
cdk4/6, et, lhrh combo improves pfs in premenopausal breast cancer
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
-
4:19
asco: new treatment (t-dm1) for her2-positive advanced breast cancer?
-
3:16
dual her2 blockade defers breast cancer in cleopatra
-
3:08
adding ribociclib to endocrine therapy shows an improvement in invasive dfs in hr /her2 bc patients
-
3:07
breast cancer drug t-dm1 shows promise in trial
-
2:02
katherine trial: t-dm1 cuts her2-positve invasive breast cancer recurrence
-
6:13
cleopatra: success with dual her2 blockade in breast cancer
-
3:18
adjuvant chemotherapy boosts survival in locoregional recurrent breast cancer
-
4:11
ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic br...
-
0:36
maintenance w/ et ribociclib after 1l chemotherapy in hr /her2- metastatic breast cancer
-
2:46
right choice: ribociclib et vs combo chemo in aggressive hr /her2− advanced breast cancer
-
0:59
ribociclib in adjuvant hr breast cancer
-
4:17
ctc matches md judgment for mbc therapeutic choice
-
5:12
monaleesa-3: ribociclib plus fulvestrant in hr mbc
-
4:06
her2 patients may do fine with local therapies alone